Vaccinex Inc (VCNX)

[Yarikd]

Still waiting...

[Yarikd]

Out of curiosity, what Monday are you referring to?

[Isrgo]

Is coming moonnnnnn

[steviaw]

Come on $12 pps Monday on huge news incoming

[steviaw]

The train has left the station. This stock is so ready to moon$$$

[steviaw]

This is classic VCNX get everyone to dump your shares before it explodes $7-$12 near term and without a doubt with these catalysts.

[Isrgo]

Dudo

[Isrgo]

????

[moondogaz]

2%?

[Yarikd]

Forget about crazy gains and pump and dump, the insiders are buying insane amounts, if that's not an indicator, what is. Look into it. Do yourself a favor do some DD.

[rolo731]

Sorry guys, you are missing the train. If you haven't looked at this one you haven't been paying attention...!

Insiders buying millions of dollars of shares here...! FACT from SEC filings

[rolo731]

That's quite possible...?

[urge2surge]

Yep...still holding. Could be a buyout in play here.

[rolo731]

Amen brother...! Something here's going on in a positive way. Give it some time and we may be very surprised...!??

[rolo731]

Smart move my friend...! You will not be disappointed cuz I feel this is a $2 and above stock...! And with the Insiders buying two to three million shares each this is most assuredly going up...MHO

[stokbrokin]

I got it this am on the opening!! First time in forever i caught a break!! Gltua peace stok

[rolo731]

How many missed this one...!

[urge2surge]

Been on a downward spiral for ever and ever here. Trades over and beyond the entire outstanding shares and drops. A text book case for the negative affects of naked shorting.
Buyout? Anything is possible. A lot of small cap bios are ripe for value buys by big pharma. The tax write offs alone, are probably worth more than what the current market cap is for VCNX.

[rolo731]

Could we be seeing a potential buyout from Merck or others...?

[ALERTS100%to10000%GAIN]

news is great lets go

[ALERTS100%to10000%GAIN]

NEWS!!! Vaccinex : Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer's Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
06/08/2021 | 07:01am EDT
share with twitter
share with LinkedIn
share with facebook
ROCHESTER, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that the first clinical sites have been activated to screen and enroll patients in its Phase 1/2 study evaluating pepinemab as a single agent in Alzheimer’s disease (AD) and in its phase 2 study in of pepinemab combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as front-line treatment for advanced, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The Company plans to activate at least 13 U.S. sites for the Alzheimer study and 18 U.S. sites for HNSCC.

The Alzheimer’s proof-of-concept study is expected to enroll at least 40 patients with key efficacy endpoints that include measures of cognition and brain imaging. This study has received funding support from the Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association. The HNSCC study will enroll up to 65 patients allocated to different levels of combined positive score (The HNSCC study is expected to enroll up to 65 patients allocated to different levels of combined positive score (CPS) of PD-L1 expression. CPS is a biomarker associated with benefit in response to immunotherapy. Efficacy endpoints will focus on objective response rate (ORR) per RECIST 1.1 criteria, as well as progression-free survival (PFS), overall survival (OS) and duration of response (DOR).

Dr. Maurice Zauderer, chief executive officer of Vaccinex, stated, “With this Alzheimer’s study, we are building on prior data from our SIGNAL phase 2 study in Huntington’s disease that we believe indicated cognitive benefit to patients at an early stage of this devastating neurodegenerative disease. It was particularly encouraging that this was accompanied by evidence of increased brain metabolic activity which has been shown in several independent studies to correlate with cognitive change in AD as well. AD patients are in urgent need of new therapies to effectively slow or halt disease progression, and we are looking forward to results from this important study.

“In addition, we recently published results of a prior phase 2 study of pepinemab in combination with a checkpoint inhibitor, EMD Serono’s Bavencio®, that we believe indicated treatment benefit to patients with non-small cell lung cancer. We are pleased to have now initiated this new trial in HNSCC in collaboration with Merck, a global immunotherapy leader. We and others have shown that SEMA4D is highly expressed in head and neck cancer and triggers increased levels of myeloid-derived suppressor cells that inhibit immune responses to tumor, providing a compelling scientific rationale for this study,” Dr. Zauderer concluded.

Multiple prior preclinical studies suggested that inhibition of SEMA4D has unique mechanisms of action that reduce activation of inflammatory glial cells in brain but increases immune infiltration and alters the balance of cytotoxic and immunosuppressive cells in a tumor microenvironment. The Company is pleased and excited to have the opportunity to develop this potentially promising therapy in multiple important indications.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Bavencio® is a registered trademark of EMD Serono, Inc., the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany.

Forward Looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements about the Company’s plans, expectations and objectives with respect to the results and timing of clinical trials of pepinemab in various indications, the use and potential benefits of pepinemab in Huntington’s and Alzheimer’s disease and other indications, and other statements identified by words such as “may,” “will,” “appears,” “expect,” “planned,” “anticipate,” “estimate,” “intend,” “hypothesis,” “potential,” “advance,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of the Company’s research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to the Company’s dependence on its lead product candidate pepinemab, the ability to leverage its ActivMAb® platform, the impact of the COVID-19 pandemic, and other matters that could affect its development plans or the commercial potential of its product candidates. Except as required by law, the Company assumes no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in the Company’s periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in the Company’s Form 10-K for year end December 31, 2021 and subsequent filings with the SEC.

Investor Contact
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
[e-mail]



Primary Logo
Source: Vaccinex, Inc.
2021 GlobeNewswire, Inc., source Press Releases

[ALERTS100%to10000%GAIN]

nice

[Bertsllc]

going to bust out...

[ALERTS100%to10000%GAIN]

3.59 high PM

[ALERTS100%to10000%GAIN]

good morning nice move here,$3.35

[ALERTS100%to10000%GAIN]

wow lets see $10++ here

[Bertsllc]

Here's why the run...

FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pa...

https://ih.advfn.com/stock-market/NASDAQ/biogen-BIIB/stock-news/85301613/fda-grants-accelerated-approval-for-aduhelm-as-th


Speculation that FDA will also grant approval for VCNX

[Bertsllc]

i think it was at about 3.27 you can link back to where my 1st post is. i thought i had bottom... pft!
average is down to 2.80 now

[ALERTS100%to10000%GAIN]

what the highest price you bought?

[ALERTS100%to10000%GAIN]

first time buy at $2.98

[Bertsllc]

spent a fortune averaging down. nice to be green again

[ALERTS100%to10000%GAIN]

VCNX~~nice bullish daily and weekly here https://stockcharts.com/freecharts/gallery.html?vcnx

[ALERTS100%to10000%GAIN]

crazy buys at $3.09 ah

[ALERTS100%to10000%GAIN]

correct something is coming, possible to see $10+++ again

[Bertsllc]

i don't think this is a technical move. Some big blocks went through at 2.30 mostly in 5000 blocks. Something is coming IMO

[ALERTS100%to10000%GAIN]

Event Details
BIO Digital International Convention
Jun 14 - 06/18/21
Webcast Presentation

https://ir.vaccinex.com/events/event-details/bio-digital-international-convention

[ALERTS100%to10000%GAIN]

VCNX~$3.10 ah

[ALERTS100%to10000%GAIN]

tomorrow break out

[ALERTS100%to10000%GAIN]

had spikes above $10+++

[ALERTS100%to10000%GAIN]

very bullish on all charts

[ALERTS100%to10000%GAIN]

got some

[wesley_]

$3.00 nice

[Bertsllc]

Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research

https://finance.yahoo.com/news/vaccinex-announces-publication-results-classical-120000937.html

[Bertsllc]

April 7, 2021...
The combination of pepinemab with avelumab was well tolerated in NSCLC and showed signs of antitumor activity in immunotherapy resistant and PD-L1 negative / low tumors.
https://clincancerres.aacrjournals.org/content/early/2021/04/06/1078-0432.CCR-20-4792


Insiders buying bigly

look-em-up
VCNX News: Statement of Changes in Beneficial Ownership (4) 04/02/2021 04:28:58 PM
VCNX News: Statement of Changes in Beneficial Ownership (4) 04/02/2021 04:28:01 PM
VCNX News: Statement of Changes in Beneficial Ownership (4) 04/02/2021 04:26:21 PM
VCNX News: Statement of Changes in Beneficial Ownership (4)

[Bertsllc]

#vaccinex $VCNX Conclusions: The combination of pepinemab with avelumab was well tolerated in NSCLC and showed signs of antitumor activity in immunotherapy resistant and PD-L1 negative / low tumors.
Down pointing backhand index
5 april 2021!!!

https://clincancerres.aacrjournals.org/content/early/2021/04/02/1078-0432.CCR-20-4792

[Bertsllc]

MERCK!
From MarketWatch Feb 19th

Shares of Vaccinex Inc. soared toward a record rally on record volume Friday, after the biotechnology company announced the signing of multiple-project deals with two "prominent" pharmaceutical companies. The collaborations will focus on the use of Vaccinex's antibody discovery and novel viral display platform, ActivMAb, for antibody discovery. ((The names of the drug makers and the financial terms over the deals were not disclosed
)).

https://finance.yahoo.com/m/1b1266df-ec7c-394a-a45b-bded26f1b66d/vaccinex-s-stock-soars-toward.html





I did some poking around today and found this,,,



https://clinicaltrials.gov/ct2/show/NCT04815720?term=vaccinex&draw=2&rank=4

[Bertsllc]

not quit. And i missed the plunge yesterday but happy with the shares i have. Now to take it up and build some support

[T695]

Might’ve time to buy buy buy

[Bertsllc]

I hope that was bottom cause i nailed it Now release the p/r were you say who the Pharma Co's are
https://finance.yahoo.com/m/1b1266df-ec7c-394a-a45b-bded26f1b66d/vaccinex-s-stock-soars-toward.html

[zmster2033]

Nice day here today. Hoping it continues next week!